GGrantIndex
Sort

50,496 grants matching lung cancer

Metabolic Engineering for Microbial Taxol Biosynthesis

$667,475
Gregory Stephanopoulos · Massachusetts Institute Of Technology · R01 · FY2009 · GM

The Role of TIMPs in Cell Growth, Tumor Progression and Metastasis

$667,359
William Stetler-Stevenson · Division Of Clinical Sciences - Nci · ZIA · FY2016 · CA

Advancing Communication Science to Reduce Disparities in Young Adult Cigar Use

$667,344
Adam O Goldstein · Univ Of North Carolina Chapel Hill · U54 · FY2024 · DA

Molecular Risk Stratification for Colonoscopic Surveillance

$667,236
Andrew T Chan · Massachusetts General Hospital · U01 · FY2017 · CA

Use of advanced imaging techniques to improve diagnostic methods for ARDS

$667,217
Ednan K. Bajwa · Massachusetts General Hospital · R01 · FY2015 · HL

Occupational and Environmental Determinants of Cancer among Women and Minorities

$667,212
Wong Chow · Cancer Epidemiology And Genetics · Z01 · FY2007 · CA

Sequencing Familial Lung Cancer

$667,196
Christopher I. Amos · Baylor College Of Medicine · U01 · FY2021 · CA

Identifying and disabling new pathways for macromolecular recycling in pancreatic cancer

$667,118
Rushika Miriam Perera · University Of California, San Francisco · R01 · FY2025 · CA

Directed Transport Physics and Muli-Scale Therapy of Colon Cancer Liver Metatasis

$667,071
Mauro Ferrari · Methodist Hospital Research Institute · U54 · FY2013 · CA

Marshfield Community Clinical Oncology Program

$667,064
Matthias Weiss · Marshfield Clinic Research Foundation · U10 · FY2007 · CA

Cellular Basis Of Action Of Gastrointestinal Peptides/Growth factors

$666,971
Robert Jensen · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2012 · DK

Core B - The Clinical and Biomarkers Core

$666,961
Dorothy K Hatsukami · University Of Minnesota · P01 · FY2017 · CA

Arsenic and the Human Genome: susceptibility and response to exposure

$666,959
Brandon Lee Pierce · University Of Chicago · R35 · FY2021 · ES

Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer

$666,956
Benjamin G. Neel · New York University School Of Medicine · R01 · FY2024 · CA

Methylation and mutations in RB1 and variants of synthetic folic acid metabolism

$666,923
Manuela A Orjuela · Columbia University Health Sciences · R01 · FY2015 · CA

Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers

$666,846
Derek Ronald Duckett · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2022 · CA

Development of lisinopril for post-exposure mitigation of late effects from a rad

$666,841
Meetha M Medhora · Medical College Of Wisconsin · U01 · FY2015 · AI

Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases

$666,767
Elizabeth Gerstner · Massachusetts General Hospital · R01 · FY2022 · CA

Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases

$666,767
Elizabeth Gerstner · Massachusetts General Hospital · R01 · FY2023 · CA

Advancing Tobacco Use Treatment for African American Smokers

$666,742
Lisa Sanderson Cox · University Of Kansas Medical Center · R01 · FY2014 · DA

Rhesus HHV-8 homologue in AIDS-related malignancies

$666,638
Scott W Wong · Oregon Health & Science University · R01 · FY2015 · CA

Minimally invasive microwave antennas for image-guided focal tumor ablation

$666,601
Richard William Schefelker · Neuwave Medical, Inc. · R44 · FY2010 · CA

COPD cachexia: deciphering the impact of antioxidants, iron and mitochondrial function using 'omics approaches

$666,481
Merry-Lynn Noelle McDonald Donnelly · University Of Alabama At Birmingham · R01 · FY2021 · HL

Caregiver Coping Skills training for Lung Cancer

$666,321
Duke University · R01 · FY2005 · CA

Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers

$666,289
Derek Ronald Duckett · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2023 · CA